MECHANISM OF CROSS-RESISTANCE BETWEEN VINCRISTINE AND DAUNORUBICIN IN EHRLICH ASCITES TUMOR CELLSSKOVSGAARD T.1978; CANCER RES.; USA; DA. 1978; VOL. 38; NO 12; PP. 4722-4727; BIBL. 33 REF.Article

DEVELOPMENT OF RESISTANCE TO RUBIDAZONE (NSC-164011) IN EHRLICH ASCITES TUMOR IN VIVOSKOVSGAARD T.1975; CANCER CHEMOTHERAPY REP.; U.S.A.; DA. 1975; VOL. 59; NO 2; PP. 301-308; BIBL. 18 REF.Article

MECHANISMS OF RESISTANCE TO DAUNORUBICIN IN EHRLICH ASCITES TUMOR CELLS.SKOVSGAARD T.1978; CANCER RES.; USA; DA. 1978; VOL. 38; NO 6; PP. 1785-1791; BIBL. 33 REF.Article

TRANSPORT AND BINDING OF DAUNORUBICIN, ADRIAMYCIN, AND RUBIDAZONE IN EHRLICH ASCITES TUMOUR CELLS.SKOVSGAARD T.1977; BIOCHEM. PHARMACOL.; G.B.; DA. 1977; VOL. 26; NO 3; PP. 215-222; BIBL. 37 REF.Article

INCREASED UPTAKE OF ACTINOMYCIN D IN EHRLICH ASCITES TUMOUR CELLS INDUCED BY DAUNORUBICINLUND ANDERSEN C; SKOVSGAARD T; NISSEN NI et al.1983; CANCER CHEMOTHERAPY AND PHARMACOLOGY; ISSN 0344-5704; DEU; DA. 1983; VOL. 10; NO 2; PP. 79-83; BIBL. 12 REF.Article

P-glycoprotein as multidrug transporter : a critical review of current multidrug resitant cell linesNIELSEN, D; SKOVSGAARD, T.Biochimica et biophysica acta. Molecular basis of disease. 1992, Vol 1139, Num 3, pp 169-183Article

Ahead of its peersKNUDSEN, A; SKOVSGAARD, T.Concrete engineering international. 1999, Vol 3, Num 6, pp 58-61, issn 1460-5856Article

INTERMITTENT HIGH-DOSE ACLARUBICIN IN PATIENTS WITH ADVANCED CANCER: A PHASE I STUDY WITH SPECIAL REFERENCE TO CARDIAC TOXICITY = ACLARUBICINE INTERMITTENTE A HAUTE DOSE DANS LES TUMEURS AVANCEES: ETUDE PHASE I AVEC MENTION PARTICULIERE POUR LA TOXICITE CARDIAQUEAABO K; MORTENSEN SA; SKOVSGAARD T et al.1983; CANCER TREATMENT REPORTS; ISSN 0361-5960; USA; DA. 1983; VOL. 67; NO 3; PP. 281-282; ABS. ENG; BIBL. 12 REF.Article

Kinetics of daunorubicin transport in ehrlich ascites tumor cells with different expression of P-glycoprotein : influence of verapamilNIELSEN, D; MAARE, C; SKOVSGAARD, T et al.Biochemical pharmacology. 1994, Vol 47, Num 12, pp 2125-2135, issn 0006-2952Article

Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cellsFRICHE, E; SKOVSGAARD, T; NISSEN, N. I et al.Cancer chemotherapy and pharmacology. 1987, Vol 19, Num 1, pp 35-39, issn 0344-5704Article

Cellular resistance to anthracyclinesNIELSEN, D; MAARE, C; SKOVSGAARD, T et al.General pharmacology. 1996, Vol 27, Num 2, pp 251-255, issn 0306-3623Article

CLINICAL TRIAL OF RUBIDAZONE IN SOLID TUMORS AND MALIGNANT LYMPHOMAS.SKOVSGAARD T; HANSEN HH; MOURIDSEN HT et al.1978; CANCER TREATM. REP.; USA; DA. 1978; VOL. 62; NO 7; PP. 1053-1058; BIBL. 23 REF.Article

Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patientsJENSEN, B. V; SKOVSGAARD, T; NIELSEN, S. L et al.Annals of oncology. 2002, Vol 13, Num 5, pp 699-709, issn 0923-7534Article

Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancerHANSEN, F; STENBYGAARD, L; SKOVSGAARD, T et al.Acta oncologica (Stockholm). 1995, Vol 34, Num 7, pp 919-924, issn 0284-186XArticle

The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cellsSEHESTED, M; SKOVSGAARD, T; ROED, H et al.Biochemical pharmacology. 1988, Vol 37, Num 17, pp 3305-3310, issn 0006-2952Article

P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicinNIELSEN, D; ERIKSEN, J; MAARE, C et al.British journal of cancer. 1998, Vol 78, Num 9, pp 1175-1180, issn 0007-0920Article

In vitro circumvention of anthracycline : resistance in Ehrlich ascites tumour by anthracycline analoguesFRICHE, E; JENSEN, P. B; ROED, H et al.Biochemical pharmacology. 1990, Vol 39, Num 11, pp 1721-1726, issn 0006-2952, 6 p.Article

Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cellsSEHESTED, M; SIMPSON, D; SKOVSGAARD, T et al.Virchows Archiv. B, Cell pathology. 1989, Vol 56, Num 5, pp 327-335, issn 0340-6075, 9 p.Article

Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulatorsSEHESTED, M; JENSEN, P. B; SKOVSGAARD, T et al.British journal of cancer. 1989, Vol 60, Num 6, pp 809-814, issn 0007-0920Article

Interaction among two subpopulations of Ehrlich ascites tumor in vivo: evidence of a contact mediated immune responseAABO, K; VINDELOV, L. L; SKOVSGAARD, T et al.Acta pathologica, microbiologica et immunologica Scandinavica. Section A. Pathology. 1987, Vol 95, Num 6, pp 325-332, issn 0108-0164Article

Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposideNIELSEN, D; MAARE, C; ERIKSEN, J et al.Biochemical pharmacology. 2000, Vol 60, Num 3, pp 353-361, issn 0006-2952Article

Epirubicin cardiotoxicity : An analysis of 469 patients with metastatic breast cancerRYBERG, M; NIELSEN, D; SKOVSGAARD, T et al.Journal of clinical oncology. 1998, Vol 16, Num 11, pp 3502-3508, issn 0732-183XArticle

Challenging drug resistance in cancer therapyLEHNE, G; ELONEN, E; BAEKELANDT, M et al.Acta oncologica (Stockholm). 1998, Vol 37, Num 5, pp 431-439, issn 0284-186XArticle

Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-upSÖLETORMOS, G; NIELSEN, D; SCHIØLER, V et al.European journal of cancer (1990). 1992, Vol 28A, Num 4-5, pp 845-850, issn 0959-8049Article

Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapyRYBERG, M; NIELSEN, D; ØSTERLIND, K et al.Annals of oncology. 2001, Vol 12, Num 1, pp 81-87, issn 0923-7534Article